AlloVir

Today AlloVir announced that it will stop three ongoing Phase 3 trials of its lead multi-virus-specific T cell therapy, posoleucel, for futility. Learn more here: ir.allovir.com/news-releases/…

This #Tcell therapy is a living investigational drug, comprised of both CD8+ and CD4+ virus-specific T cells that expand in the presence of viral antigens, selectively killing the virus-infected cells. (2/2) Explore the science: allovir.com/our-platform

Posoleucel is an investigational #Tcell therapy designed to target six common viruses that can have devastating consequences for people with immune deficiency. (1/2) Learn more here: allovir.com/our-platform

Earlier this week our team gathered to celebrate the upcoming holiday season and reflect on our accomplishments in 2023. We are excited for the progress we have made this year with our lead investigational therapy, posoleucel. #celebration #biotechnology #culture

In case you missed it, AlloVir's CEO, Diana Brainard, participated in a fireside chat during the @PiperSandler 35th Annual Healthcare Conference. To learn more about AlloVir and our VST platform, listen here: #biotechnology" target="_blank" rel="nofollow noopener">ir.allovir.com/events-and-pre… #celltherapy #investmentbanking

November is the time of year when we take a moment to pause and reflect on all we are grateful for in our lives. This year, we asked our colleagues at AlloVir to let us know what they are thankful for. See some of their responses below! #ExCELLenceAtAlloVir #biotechnology

Join our CEO, Diana Brainard, MD, for a fireside chat at the @Piper_Sandler 35th Annual Healthcare Conference on Tuesday November 28th, at 10AM ET. Learn more here: ir.allovir.com/events-and-pre… #biotechnology #investmentbanking $ALVR

Our CEO, Diana Brainard, MD, sat down with biotech reporter Luke Timmerman for his podcast, “The Long Run with Luke Timmerman” to discuss her background and the impact virus-specific T cells could have on infectious diseases. Listen to the episode here: soundcloud.com/longrunpodcast…

On Veteran's Day, we would like to take a moment to recognize the brave individuals who have helped protect our country and keep us safe at home and abroad. Thank you for your service. #veteransday

Posoleucel has the potential to transform care for transplant recipients. #celltherapy #innovation #biotechnology (3/3)

Our investigational T cell therapy, posoleucel, seeks to treat or prevent six common but devastating viruses: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus, (EBV), human herpesvirus (HHV-6), and JC virus (JCV). (2/3)

More than 80% of allo-HCT patients reactivate one or more viruses and with limited to no treatment options when patients do reactivate a virus, there is a high unmet need within this population. (1/3)

Dr. Cardarelli will present data from AlloVir's Phase 2 trial of our multi-virus specific #tcell therapy, posoleucel, in kidney transplant patients with BK viremia. #clinicaltrials (2/2)

Join Francesca Cardarelli, M.D., AlloVir’s Senior Director of Clinical Development, on Saturday, November 4th at @ASNKidney's #KidneyWk. (1/2)

This morning AlloVir announced its third quarter 2023 financial results. Learn more here: ir.allovir.com/press-releases

Are you attending #IDWeek2023? If so, join AlloVir's Senior Vice President of Clinical Research, Dr. Richard Riese, on Thursday morning for a presentation on our lead investigational #Tcell therapy, posoleucel! #biotech

ALVR106 is one of our investigational multi-virus specific #Tcell therapies which targets RSV as well as influenza, parainfluenza and human metapneumovirus. Learn more here: allovir.com/products/alvr1…

October is National #RSVAwareness month. Respiratory syncytial virus (RSV) can cause serious complications for allo-HCT patients including upper and lower respiratory tract infections and RSV pneumonia.

Meet Julia Camara, our Senior Manager of Quality Systems, Documentation, and Training. We are excited to highlight Julia's contributions to AlloVir and celebrate how her work embodies our core value of scientific excellence. #ExCELLenceatAlloVir #Corevalues

Join our Chief Scientific Officer, Dr. Ann M. Leen, for a presentation at DGTI in Berlin to learn about off-the-shelf multi-virus specific T cell therapies and their potential to treat or prevent devastating viral diseases in transplant recipients. #celltherapy #DGTI2023